Home › Companies › Denali Therapeutics Inc. › 2025-2026

Denali Therapeutics Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Denali Therapeutics Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
279Asset managers
1,645Fund votes
2026-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Denali Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Denali Therapeutics Inc.

These tallies are Denali Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Denali Therapeutics Inc. — official shareholder meeting results, meeting held 2026-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jennifer Cook	75,998,259	--	--	48,847,029	13,140,839	Majority: yes
Elect Director: David Schenkein, M.D.	91,814,688	--	--	33,030,600	13,140,839	Majority: yes
Elect Director: Ryan Watts, Ph.D.	121,220,572	--	--	3,624,716	13,140,839	Majority: yes

Source: Denali Therapeutics Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.

How asset managers voted at the Denali Therapeutics Inc. 2025-2026 meeting

Each item below shows how the 279 asset managers that disclosed a Denali Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Denali Therapeutics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, executive compensation.

SECTION 14A SAY-ON-PAY VOTES

93% fund support · no official result

FOR 92%7%

The 266 asset managers below cast 93% of the shares they voted on this item FOR (116,372,287 for, 9,411,517 against).

FOR: 116,372,287 (92.5%)AGAINST: 9,411,517 (7.5%)ABSTAIN: 43,908 (0.0%)NOT VOTED: 3,322 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, executive compensation.” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
T. Rowe Price	18,166,820	0	0	For
Vanguard	16,446,441	10	2	For
BlackRock	10,427,173	164	0	For
Fidelity	10,299,055	0	0	For
BAILLIE GIFFORD & CO LTD	8,667,248	0	0	For
State Street	5,193,587	0	0	For
BAKER BROS. ADVISORS LP	3,731,695	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,731,131	0	0	For
AllianceBernstein	3,641,352	0	0	For
BAILLIE GIFFORD OVERSEAS LTD	3,040,954	0	0	For
Capital Group	0	2,687,684	0	Against
Capital Research Global Investors	0	2,687,684	0	Against
Charles Schwab	2,427,454	0	0	For
PICTET ASSET MANAGEMENT SA	2,402,881	0	0	For
Goldman Sachs	2,333,134	0	0	For
UBS	0	1,895,335	0	Against
Lynx1 Capital Management LP	1,880,303	0	0	For
Aberdeen	1,854,446	0	0	For
Fisher Asset Management, LLC	1,491,431	0	0	For
Siren, L.L.C.	1,396,513	0	0	For
American Century	0	1,385,465	0	Against
Foresite Capital Management VI LLC	1,209,971	0	0	For
Candriam S.C.A.	1,099,845	0	0	For
Dimensional	1,065,377	0	0	For
Northern Trust	1,040,298	0	0	For

Showing the 25 largest of 266 asset managers. See all 266 in the interactive database.

2. ELECTION OF DIRECTORS: David Schenkein, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 91,814,688WITHHELD: 33,030,600

Denali Therapeutics Inc.’s own tally for this item (“Elect Director: David Schenkein, M.D.”): 91,814,688 for, 33,030,600 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 158,656,318 outstanding shares: 58% for, 21% withheld (79% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (37,281,142 for, 0 against).

FOR 78%ABSTAIN 22%

FOR: 37,281,142 (77.6%)ABSTAIN: 10,780,054 (22.4%)

Largest asset managers voting on “ELECTION OF DIRECTORS: David Schenkein, M.D.” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	15,259,197	87	For
T. Rowe Price	1,705,163	5,207,668	Abstain
Fidelity	5,767,405	0	For
BlackRock	5,584,177	0	For
Capital Group	2,687,684	0	For
State Street	2,401,485	2,712	For
Charles Schwab	1,207,165	0	For
AllianceBernstein	0	895,718	Abstain
Principal	0	792,720	Abstain
Dimensional	0	752,453	Abstain
Goldman Sachs	694,627	0	For
American Century	0	660,212	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	608,609	Abstain
Equitable	212,430	333,761	Abstain
TIAA	278,450	0	For
QUANTITATIVE MASTER SERIES LLC	230,704	0	For
Jackson National	0	178,812	Abstain
Brighthouse	70,898	91,426	Abstain
BNY Mellon	156,361	5,106	For
Lincoln Financial	101,423	51,347	For
JPMorgan	138,960	0	For
Segall Bryant & Hamill Trust	0	138,028	Abstain
Invesco	121,891	0	For
OPTIMUM FUND TRUST	0	114,524	Abstain
ALPS ETF Trust	0	110,155	Abstain

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

3. ELECTION OF DIRECTORS: Jennifer Cook

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

61% Majority: yes · of votes cast

FOR 61%WITHHELD 39%

FOR: 75,998,259WITHHELD: 48,847,029

Denali Therapeutics Inc.’s own tally for this item (“Elect Director: Jennifer Cook”): 75,998,259 for, 48,847,029 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 158,656,318 outstanding shares: 47.9% for, 31% withheld (79% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (28,911,364 for, 0 against).

FOR 60%ABSTAIN 40%

FOR: 28,911,364 (60.2%)ABSTAIN: 19,149,832 (39.8%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Jennifer Cook” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	15,251,294	7,990	For
T. Rowe Price	1,705,163	5,207,668	Abstain
Fidelity	5,705,270	62,135	For
BlackRock	558,168	5,026,009	Abstain
Capital Group	2,687,684	0	For
State Street	4,788	2,399,409	Abstain
Charles Schwab	1,207,165	0	For
AllianceBernstein	0	895,718	Abstain
Principal	0	792,720	Abstain
Dimensional	0	752,453	Abstain
Goldman Sachs	694,627	0	For
American Century	0	660,212	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	608,609	Abstain
Equitable	8,698	537,493	Abstain
TIAA	278,450	0	For
QUANTITATIVE MASTER SERIES LLC	0	230,704	Abstain
Jackson National	0	178,812	Abstain
Brighthouse	70,898	91,426	Abstain
BNY Mellon	156,361	5,106	For
Lincoln Financial	12,023	140,747	Abstain
JPMorgan	138,960	0	For
Segall Bryant & Hamill Trust	0	138,028	Abstain
Invesco	121,891	0	For
OPTIMUM FUND TRUST	0	114,524	Abstain
ALPS ETF Trust	0	110,155	Abstain

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. ELECTION OF DIRECTORS: Ryan Watts, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 121,220,572WITHHELD: 3,624,716

Denali Therapeutics Inc.’s own tally for this item (“Elect Director: Ryan Watts, Ph.D.”): 121,220,572 for, 3,624,716 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 158,656,318 outstanding shares: 76% for, 2% withheld (79% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (47,151,247 for, 0 against).

FOR 98%

FOR: 47,151,247 (98.1%)ABSTAIN: 909,950 (1.9%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Ryan Watts, Ph.D.” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	15,259,274	10	For
T. Rowe Price	6,912,831	0	For
Fidelity	5,767,405	0	For
BlackRock	5,584,177	0	For
Capital Group	2,687,684	0	For
State Street	2,404,173	24	For
Charles Schwab	1,207,165	0	For
AllianceBernstein	895,718	0	For
Principal	792,720	0	For
Dimensional	0	752,453	Abstain
Goldman Sachs	694,627	0	For
American Century	660,212	0	For
AB DISCOVERY GROWTH FUND, INC.	608,609	0	For
Equitable	546,191	0	For
TIAA	278,450	0	For
QUANTITATIVE MASTER SERIES LLC	230,704	0	For
Jackson National	147,258	31,554	For
Brighthouse	118,499	43,825	For
BNY Mellon	161,467	0	For
Lincoln Financial	145,338	7,432	For
JPMorgan	138,960	0	For
Segall Bryant & Hamill Trust	138,028	0	For
Invesco	121,891	0	For
OPTIMUM FUND TRUST	114,524	0	For
ALPS ETF Trust	110,155	0	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 69 asset managers below cast 99.9% of the shares they voted on this item FOR (47,997,811 for, 95 against).

FOR: 47,997,811 (99.9%)AGAINST: 95 (0.0%)ABSTAIN: 43,825 (0.1%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	15,259,283	1	0	For
T. Rowe Price	6,912,831	0	0	For
Fidelity	5,767,405	0	0	For
BlackRock	5,584,177	0	0	For
Capital Group	2,687,684	0	0	For
State Street	2,404,103	94	0	For
Charles Schwab	1,207,165	0	0	For
AllianceBernstein	895,718	0	0	For
Principal	792,720	0	0	For
Dimensional	752,453	0	0	For
Goldman Sachs	694,627	0	0	For
American Century	660,212	0	0	For
AB DISCOVERY GROWTH FUND, INC.	608,609	0	0	For
Equitable	546,191	0	0	For
TIAA	278,450	0	0	For
QUANTITATIVE MASTER SERIES LLC	230,704	0	0	For
Jackson National	178,812	0	0	For
Brighthouse	118,499	0	43,825	For
BNY Mellon	161,467	0	0	For
Lincoln Financial	152,770	0	0	For
JPMorgan	138,960	0	0	For
Segall Bryant & Hamill Trust	138,028	0	0	For
Invesco	121,891	0	0	For
OPTIMUM FUND TRUST	114,524	0	0	For
ALPS ETF Trust	110,155	0	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 10 asset managers below cast 100% of the shares they voted on this item FOR (397,803 for, 0 against).

FOR: 397,803 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Vote
GROUPAMA ASSET MANAGMENT	211,977	For
SECTOR GAMMA AS	128,094	For
Rhumbline	33,590	For
VALUED ADVISERS TRUST	18,058	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	2,916	For
CLEARWATER INVESTMENT TRUST	1,765	For
Orion Porfolio Solutions, LLC	861	For
Mowery & Schoenfeld Wealth Management, LLC	500	For
Coyle Financial Counsel LLC	42	For
Temasek Holdings (Private) Ltd	0	--

7. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

9% fund support · no official result

9%AGAINST 91%

The 2 asset managers below cast 9% of the shares they voted on this item FOR (1,765 for, 18,058 against).

FOR: 1,765 (8.9%)AGAINST: 18,058 (91.1%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at Denali Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
VALUED ADVISERS TRUST	0	18,058	0	0	Against
CLEARWATER INVESTMENT TRUST	1,765	0	0	0	For

Largest Denali Therapeutics Inc. shareholders voting in 2025-2026

Ranked by the number of Denali Therapeutics Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 158,656,318 shares outstanding at the time of that meeting.

Top Denali Therapeutics Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	11.45%
2	Vanguard	10.37%
3	BlackRock	6.57%
4	Fidelity	6.49%
5	BAILLIE GIFFORD & CO LTD	5.46%
6	State Street	3.27%
7	BAKER BROS. ADVISORS LP	2.35%
8	GEODE CAPITAL MANAGEMENT, LLC	2.35%
9	AllianceBernstein	2.30%
10	BAILLIE GIFFORD OVERSEAS LTD	1.92%

Reported Denali Therapeutics Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Denali Therapeutics Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	8.23%	13F
BlackRock	8.22%	13F
BAILLIE GIFFORD & CO	7.54%	13G
FMR LLC	5.38%	DEF14A
Julian C. Baker	5.13%	DEF14A
State Street	3.95%	13F
FMR (Fidelity)	2.88%	13F
Goldman Sachs	2.78%	13F
Ryan J. Watts, Ph.D.	2.68%	DEF14A
Geode Capital	2.35%	13F

Percentages above are of 158,656,318 shares outstanding, as reported by Denali Therapeutics Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Denali Therapeutics Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Denali Therapeutics Inc.'s shareholder meeting held 2026-06-03, in the 2025-2026 proxy season, 279 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,645 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Denali Therapeutics Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, executive compensation. — the reporting funds cast 93% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Denali Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).